Ke‐Da Yu

10.4k citations
173 papers · 5.9k indexed · 2 hit papers · h-index 40

Impact in

    • Breast Cancer Treatment Studies
    • Cancer-related molecular mechanisms research
    • Cancer Genomics and Diagnostics
    • MicroRNA in disease regulation
  • Oncology top 1%
    • HER2/EGFR in Cancer Research
    • Cancer Cells and Metastasis

Papers in

    • Breast Cancer Treatment Studies 59
    • Cancer Genomics and Diagnostics 19
    • Cancer-related molecular mechanisms research 12
    • HER2/EGFR in Cancer Research 41

Ke‐Da Yu

163 papers receiving 5.8k citations

Hit Papers

Breast cancer: pathogenesis and treatments 2025 · 145 citations
14520142026201820222505007501000

Peers

Ke‐Da Yu
Comparison fields: 5 of 145
  • Cancer Research 2.4k
  • Oncology 2.5k
  • Pathology and Forensic Medicine 614
  • Molecular Biology 2.2k
  • Pulmonary and Respiratory Medicine 890
Replace Xiaojiang Cui with:
Xiaojiang Cui United States
Taina Turpeenniemi‐Hujanen Finland
Elizabeth Claire Dees United States
Bhaskar Kallakury United States
Francisco J. Vizoso Spain
Rui Manuel Reis Brazil
Glen J. Weiss United States
William G. Cance United States
Antonio Jimeno United States
Ricardo D. Coletta Brazil
Ke‐Da Yu relative to Xiaojiang Cui United States Xiaojiang Cui's profile →
Citations per field
00.5×1.5×2.1×
Xiaojiang Cui · 1×
Citations per year

Countries citing papers authored by Ke‐Da Yu

Since Specialization
Citations

This map shows the geographic impact of Ke‐Da Yu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ke‐Da Yu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ke‐Da Yu more than expected).

Fields of papers citing papers by Ke‐Da Yu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ke‐Da Yu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ke‐Da Yu. The network helps show where Ke‐Da Yu may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Ke‐Da Yu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ke‐Da Yu Line = papers co-authored together Ke‐Da Yu links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown
#Work
1 20252
2 20253
3 20230
4 202339
5 202289
6 202241
7 20221
8 2022114
9 20226
10 202137
11 202046
12 202023
13 2019265
14 201671
15 2016157
16 20158
17 201435
18 2013127
19 201123
20 198310

About Ke‐Da Yu

Ke‐Da Yu is a scholar working on Cancer Research, Oncology, Pathology and Forensic Medicine, Genetics and Immunology and Allergy, having authored 173 papers that have together received 5.9k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (59 papers), HER2/EGFR in Cancer Research (41 papers), Breast Lesions and Carcinomas (22 papers), Estrogen and related hormone effects (21 papers), Cancer Genomics and Diagnostics (19 papers), Advanced Breast Cancer Therapies (14 papers), BRCA gene mutations in cancer (13 papers) and Cancer-related molecular mechanisms research (12 papers). The work is most often cited by research in Cancer Research (2.4k citations), Oncology (2.5k citations), Pathology and Forensic Medicine (614 citations), Molecular Biology (2.2k citations) and Pulmonary and Respiratory Medicine (890 citations). Ke‐Da Yu has collaborated with scholars based in China, United States and United Kingdom. Frequent co-authors include Zhi‐Ming Shao, Lei Fan, Jun-Jie Li, Jessica St. Louis, Dianne M. Finkelstein, Paul E. Goss, Kathrin Strasser‐Weippl, Jiong Wu, Yi-Zhou Jiang and Gen‐Hong Di. Their work appears in journals such as Breast Cancer Research and Treatment, Cancer Research, Oncotarget, PLoS ONE and Clinical Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026